Funder: National Institutes of Health

Due Dates: January 3, 2025 (Letter of Intent) | February 5, 2025 (New) | March 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision)

Funding Amounts: No budget limit; up to 5 years for analytical+clinical or clinical validation, 4 years for analytical only; budgets must reflect actual project needs.

Summary: Supports rigorous analytical and/or clinical validation of biomarkers for Alzheimer's disease and related dementias to accelerate their use in therapy development, clinical trials, and clinical practice.

Key Information: Clinical trial optional; non-domestic (non-U.S.) entities are eligible; projects proposing biomarker discovery or non-human studies are not responsive.